-
New Hope for Social Anxiety: Promising Results from VistaGen’s Phase 3 PALISADE-4 Study
NASDAQ: $VTGN A Breakthrough in Social Anxiety Treatment For millions living with Social Anxiety Disorder (SAD), finding effective relief can be a long and challenging journey. Recent clinical updates from VistaGen offer a glimmer of optimism. The company has announced preliminary positive data from the open-label extension portion of its Phase 3 PALISADE-4 study, evaluating…